XNCR - Xencor Inc Stock Price, Fair Value and News

$24.13+0.12 (+0.50%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

XNCR Price Action

Last 7 days

0.4%

Last 30 days

1.7%

Last 90 days

14.5%

Trailing 12 Months

18.1%

XNCR RSI Chart

XNCR Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-8.52

Price/Sales (Trailing)

19.83

EV/EBITDA

-13.24

Price/Free Cashflow

57.87

XNCR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XNCR Fundamentals

XNCR Revenue

Revenue (TTM)

85.2M

Rev. Growth (Yr)

-81.9%

Rev. Growth (Qtr)

-36.85%

XNCR Earnings

Earnings (TTM)

-198.2M

Earnings Growth (Yr)

-86.01%

Earnings Growth (Qtr)

31.56%

XNCR Profitability

EBT Margin

-177.67%

Return on Equity

-27.39%

Return on Assets

-20.15%

Free Cashflow Yield

1.73%

XNCR Investor Care

Shares Dilution (1Y)

14.96%

Diluted EPS (TTM)

-3.19

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	162.2M	133.6M	85.2M	0
2023	98.0M	113.4M	145.3M	168.3M
2022	326.6M	289.4M	297.0M	164.6M
2021	124.3M	178.7M	163.0M	275.1M
2020	77.1M	70.8M	84.4M	122.7M
2019	182.7M	172.0M	164.7M	156.7M
2018	0	0	78.8M	77.8M
2017	83.8M	30.3M	29.5M	53.2M
2016	33.5M	98.5M	102.8M	87.5M
2015	8.8M	9.0M	11.7M	27.8M
2014	11.0M	7.9M	5.6M	9.5M
2013	9.7M	9.8M	10.0M	10.2M
2012	0	0	0	9.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

CEO	Dr. Bassil I. Dahiyat Ph.D.
WEBSITE	xencor.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	281

Xencor Inc Frequently Asked Questions

What is the ticker symbol for Xencor Inc? What does XNCR stand for in stocks?

XNCR is the stock ticker symbol of Xencor Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xencor Inc (XNCR)?

As of Fri Dec 20 2024, market cap of Xencor Inc is 1.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers.

Is Xencor Inc a good stock to buy?

The fair value guage provides a quick view whether XNCR is over valued or under valued. Whether Xencor Inc is cheap or expensive depends on the assumptions which impact Xencor Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XNCR.

What is Xencor Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, XNCR's PE ratio (Price to Earnings) is -8.52 and Price to Sales (PS) ratio is 19.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XNCR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Xencor Inc's stock?

In the past 10 years, Xencor Inc has provided 0.042 (multiply by 100 for percentage) rate of return.